Compare VNRX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | CMMB |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.4M |
| IPO Year | 2012 | 2023 |
| Metric | VNRX | CMMB |
|---|---|---|
| Price | $0.17 | $1.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $13.62 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.3M | 102.3K |
| Earning Date | 11-12-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $57.67 | N/A |
| Revenue Next Year | $240.52 | N/A |
| P/E Ratio | ★ N/A | $27.00 |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $1.01 |
| 52 Week High | $3.26 | $3.44 |
| Indicator | VNRX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 26.92 | 24.22 |
| Support Level | $0.15 | N/A |
| Resistance Level | $0.18 | $1.89 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 19.34 | 5.36 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.